Itanapraced, when given orally at 375 ppm in the diet for 17 weeks, lowers both Aβ42 and Aβ40 levels and reduces brain plaque burden in Tg2576 transgenic mice^[1].

Itanapraced, at concentrations of 0.03-100 µM, inhibits Aβ secretion in human neuroglioma cells (H4swe) expressing APPswe with IC50 values of 3.6 μM for Aβ42 and 18.4 μM for Aβ40^[1].

Itanapraced, at doses of 5-200 µM, inhibits Notch processing in HEK293swe cells with effective concentrations starting at 15 µM^[1].

Itanapraced, in a range of 0-1000 µM over 30 minutes, dose-dependently suppresses action potentials with an IC50 of 106 μM^[2].

Itanapraced, at concentrations ranging from 30-100 µM, dose-dependently reduces excitatory synaptic transmission^[2].

Itanapraced, at doses of 1-10 µM, significantly diminishes cell apoptosis in hippocampal neurons caused by oxygen and glucose deprivation (OGD)^[2].